Stay updated on Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page.
Latest updates to the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe website has been updated from version 2.10.3 to 2.11.0, indicating a new release with potential enhancements or features.SummaryDifference0.1%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3, indicating a new release.SummaryDifference0.0%
- Check37 days agoNo Change Detected
- Check51 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.SummaryDifference0.0%
- Check71 days agoChange DetectedThe study has expanded to include 176 locations and has been updated from revision v2.9.7 to v2.10.0.SummaryDifference0.2%
- Check80 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.0%
- Check92 days agoChange DetectedThe value of the publication has been updated to include new findings related to the preservation of quality of life in patients with HER2-positive metastatic breast cancer treated with tucatinib or placebo in combination with trastuzumab and capecitabine, as well as intracranial efficacy and survival data from the HER2CLIMB trial.SummaryDifference0.0%
Stay in the know with updates to Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page.